Wells Fargo’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-59,152
| Closed | -$2.27M | – | 7768 |
|
|
2023
Q2 | $2.27M | Buy |
59,152
+18,911
| +47% | +$486K | ﹤0.01% | 2799 |
|
|
2023
Q1 | $932K | Buy |
40,241
+39,174
| +3,671% | +$934K | ﹤0.01% | 3425 |
|
|
2022
Q4 | $28K | Sell |
1,067
-393
| -27% | -$8.71K | ﹤0.01% | 5120 |
|
|
2022
Q3 | $29K | Buy |
1,460
+479
| +49% | +$9.61K | ﹤0.01% | 5218 |
|
|
2022
Q2 | $17K | Sell |
981
-2,756
| -74% | -$43.3K | ﹤0.01% | 5542 |
|
|
2022
Q1 | $61K | Sell |
3,737
-13,526
| -78% | -$184K | ﹤0.01% | 5559 |
|
|
2021
Q4 | $282K | Sell |
17,263
-36,860
| -68% | -$525K | ﹤0.01% | 5069 |
|
|
2021
Q3 | $690K | Buy |
54,123
+40,069
| +285% | +$527K | ﹤0.01% | 4474 |
|
|
2021
Q2 | $198K | Sell |
14,054
-61,711
| -81% | -$987K | ﹤0.01% | 5033 |
|
|
2021
Q1 | $1.18M | Buy |
75,765
+18,143
| +31% | +$296K | ﹤0.01% | 4134 |
|
|
2020
Q4 | $914K | Buy |
57,622
+1,159
| +2% | +$17.5K | ﹤0.01% | 4095 |
|
|
2020
Q3 | $686K | Sell |
56,463
-22,918
| -29% | -$307K | ﹤0.01% | 4126 |
|
|
2020
Q2 | $917K | Buy |
79,381
+69,421
| +697% | +$957K | ﹤0.01% | 3879 |
|
|
2020
Q1 | $136K | Sell |
9,960
-725
| -7% | -$8.57K | ﹤0.01% | 4907 |
|
|
2019
Q4 | $63K | Sell |
10,685
-253
| -2% | -$1.38K | ﹤0.01% | 5441 |
|
|
2019
Q3 | $58K | Buy |
10,938
+432
| +4% | +$2.87K | ﹤0.01% | 5523 |
|
|
2019
Q2 | $81K | Buy |
10,506
+4,057
| +63% | +$61.8K | ﹤0.01% | 5390 |
|
|
2019
Q1 | $129K | Sell |
6,449
-5,494
| -46% | -$95.8K | ﹤0.01% | 5042 |
|
|
2018
Q4 | $158K | Buy |
11,943
+5,830
| +95% | +$116K | ﹤0.01% | 5070 |
|
|
2018
Q3 | $225K | Buy |
6,113
+340
| +6% | +$10.9K | ﹤0.01% | 4947 |
|
|
2018
Q2 | $202K | Buy |
5,773
+132
| +2% | +$5.06K | ﹤0.01% | 5031 |
|
|
2018
Q1 | $263K | Sell |
5,641
-6,479
| -53% | -$237K | ﹤0.01% | 4826 |
|
|
2017
Q4 | $455K | Sell |
12,120
-2,451
| -17% | -$107K | ﹤0.01% | 4471 |
|
|
2017
Q3 | $776K | Buy |
14,571
+7,683
| +112% | +$456K | ﹤0.01% | 4033 |
|
|
2017
Q2 | $392K | Buy |
6,888
+2,075
| +43% | +$104K | ﹤0.01% | 4374 |
|
|
2017
Q1 | $259K | Sell |
4,813
-8
| -0.2% | -$452 | ﹤0.01% | 4656 |
|
|
2016
Q4 | $275K | Buy |
4,821
+2,369
| +97% | +$143K | ﹤0.01% | 4589 |
|
|
2016
Q3 | $152K | Buy |
2,452
+28
| +1% | +$1.98K | ﹤0.01% | 4643 |
|
|
2016
Q2 | $137K | Sell |
2,424
-1,370
| -36% | -$83.2K | ﹤0.01% | 4632 |
|
|
2016
Q1 | $243K | Buy |
3,794
+2,760
| +267% | +$223K | ﹤0.01% | 4290 |
|
|
2015
Q4 | $146K | Buy |
1,034
+887
| +603% | +$120K | ﹤0.01% | 4662 |
|
|
2015
Q3 | $15K | Sell |
147
-1,793
| -92% | -$214K | ﹤0.01% | 5622 |
|
|
2015
Q2 | $295K | Buy |
+1,940
| New | +$320K | ﹤0.01% | 4385 |
|
Wells Fargo's KDNY Position: Q3 2023 in Review
Wells Fargo sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 59,152 shares — an estimated $2.27M sold.
Wells Fargo first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $2.27M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Wells Fargo reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 59,152 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.27M.
- Wells Fargo first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- Wells Fargo's Chinook Therapeutics, Inc. Common Stock position peaked at $2.27M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.